EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer.
EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer.
复制标题
DOI：
10.2147/dddt.s69690
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Wang Z
中科院分区：
文献类型：
--
作者：
Fang S;Wang Z
非小细胞肺癌（Non-small-cell lung cancer， NSCLC）已进入个体化治疗的时代，特异癌基因点突变的增加和部分染色体重排是预测靶向治疗效果的生物标志物。目前，临床医生一致认为表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）在EGFR突变的NSCLC患者中显示出良好的疗效，一些相关研究表明，EGFR突变的存在是一个良好的预后标志。然而，EGFR突变状态与NSCLC患者对常规化疗药物的反应性和生存率之间的关系尚不清楚。这篇综述综述并评估了EGFR作为术后患者预后标志物和对细胞毒性化疗反应的预测标志物的作用。此外，我们回顾了19外显子和21外显子EGFR突变对化疗反应的比较以及p.T790M突变的预测作用。
Non-small-cell lung cancer (NSCLC) has entered the age of individual treatment, and increasing point mutations of specific oncogenes and rearrangement of some chromosomes are biomarkers used to predict the therapeutic effect of targeted therapy. At present, there is a consensus among clinicians that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown favorable efficacy in NSCLC patients with EGFR mutation, and some relevant research has suggested that the presence of EGFR mutations is a favorable prognostic marker. However, the association of EGFR mutation status with the responsiveness to conventional chemotherapy agents and survival in NSCLC patients is still unclear. This review provides an overview of and assesses the role of EGFR as a prognostic marker for postoperative patients and as a predictive marker for response to cytotoxic chemotherapy. In addition, we review the comparison of response to chemotherapy between EGFR mutations in exon 19 and in exon 21 and the predictive role of p.T790M mutation.